Loading clinical trials...

COMPLETEDPHASE2

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer

NCT00046800•Astellas Pharma Inc

View on ClinicalTrials.gov

Summary

The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Confirmed relapsed ovarian cancer.
•Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).
•One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.
•At least three weeks since prior chemotherapy and recovery from any related toxicities.
•At least four weeks since prior radiotherapy and recovery from any related toxicities.

Locations (11)

NYU- Kaplan Comprehensive Cancer Center

New York, New York, United States

The Sarah Cannon Cancer Center, Centennial Medical Center

Nashville, Tennessee, United States

St Chad's Unit

Birmingham, United Kingdom

Beatson Oncology Centre

Glasgow, United Kingdom

Royal Surrey County Hospital

Guildford, Surrey, United Kingdom

Royal Marsden NHS Trust

London, United Kingdom

Northern Centre for Cancer Research, Newcastle General Hospital

Newcastle upon Tyne, United Kingdom

Mount Vernon Hospital

Northwood, Middlesex, United Kingdom

CRC Department of Medical Oncology

Sutton Surrey, United Kingdom

Taunton & Somerset Hospital

Taunton, United Kingdom

Key Dates

Start Date

September 1, 2002

Completion Date

March 1, 2003

Last Updated

October 20, 2011

Enrollment

Estimated participants

Conditions

Ovarian Neoplasms

Interventions

OSI-211 (Liposomal Lurtotecan)

DRUG

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

Solid Tumor, AdultColorectal Cancer+18 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 20, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Inclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Establishment of a Tumor Bank for Tissue Samples

Institut Paoli Calmettes Ovarian Cancer Database